HRP20191180T1 - Imidazopirazinoni kao inhibitori pde1 - Google Patents
Imidazopirazinoni kao inhibitori pde1 Download PDFInfo
- Publication number
- HRP20191180T1 HRP20191180T1 HRP20191180TT HRP20191180T HRP20191180T1 HR P20191180 T1 HRP20191180 T1 HR P20191180T1 HR P20191180T T HRP20191180T T HR P20191180TT HR P20191180 T HRP20191180 T HR P20191180T HR P20191180 T1 HRP20191180 T1 HR P20191180T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazin
- methyl
- imidazo
- pyran
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500261 | 2015-04-30 | ||
| DKPA201500666 | 2015-10-29 | ||
| DKPA201600202 | 2016-04-04 | ||
| EP16720101.1A EP3288944B1 (en) | 2015-04-30 | 2016-04-29 | Imidazopyrazinones as pde1 inhibitors |
| PCT/EP2016/059583 WO2016174188A1 (en) | 2015-04-30 | 2016-04-29 | Imidazopyrazinones as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191180T1 true HRP20191180T1 (hr) | 2019-10-04 |
Family
ID=55910242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191180TT HRP20191180T1 (hr) | 2015-04-30 | 2016-04-29 | Imidazopirazinoni kao inhibitori pde1 |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| PT3532064T (pt) * | 2016-10-28 | 2020-09-03 | H Lundbeck As | Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| WO2018125810A1 (en) | 2016-12-28 | 2018-07-05 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| CN111655695B (zh) | 2017-11-27 | 2025-05-27 | 达特神经科学有限公司 | 作为pde1抑制剂的取代的呋喃并嘧啶化合物 |
| AR113926A1 (es) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| EP3802545A4 (en) | 2018-05-25 | 2022-03-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| WO2004099211A1 (de) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
| EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| JP2008524331A (ja) * | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| WO2007025103A2 (en) * | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
| CA2706986A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| AP2011005672A0 (en) * | 2008-09-08 | 2011-04-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of CNS disorders. |
| US8927556B2 (en) * | 2008-12-06 | 2015-01-06 | Intra-Cellular Therapies, Inc. | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds |
| JP5813511B2 (ja) * | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US8748386B2 (en) | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| SG10201509330XA (en) | 2010-08-12 | 2015-12-30 | Lilly Co Eli | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| PL2619208T3 (pl) | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN106905324B (zh) * | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| HK1199879A1 (en) | 2012-01-26 | 2015-07-24 | H.隆德贝克有限公司 | Pde9 inhibitors with imidazo triazinone backbone |
| JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
| IN2015DN00334A (OSRAM) | 2012-06-18 | 2015-06-12 | Dart Neuroscience Cayman Ltd | |
| US9598426B2 (en) | 2013-03-15 | 2017-03-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| JP6483146B2 (ja) | 2014-02-19 | 2019-03-13 | ハー・ルンドベック・アクチエゼルスカベット | アルツハイマー病治療用のｂａｃｅ１阻害剤としての２−アミノ−３，５，５−トリフルオロ−３，４，５，６−テトラヒドロピリジン |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| JP2017527606A (ja) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 三環系誘導体 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
| TW201643167A (zh) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US20180244645A1 (en) | 2015-08-12 | 2018-08-30 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
| AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| PT3532064T (pt) | 2016-10-28 | 2020-09-03 | H Lundbeck As | Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
-
2016
- 2016-04-26 JO JOP/2016/0081A patent/JO3627B1/ar active
- 2016-04-27 TW TW105113074A patent/TWI695838B/zh not_active IP Right Cessation
- 2016-04-29 SM SM20190393T patent/SMT201900393T1/it unknown
- 2016-04-29 PE PE2017002342A patent/PE20180121A1/es unknown
- 2016-04-29 RU RU2017137514A patent/RU2712219C2/ru active
- 2016-04-29 KR KR1020177030665A patent/KR102605759B1/ko active Active
- 2016-04-29 RS RS20190893A patent/RS59051B1/sr unknown
- 2016-04-29 EP EP16720101.1A patent/EP3288944B1/en active Active
- 2016-04-29 CN CN201680023903.9A patent/CN107531714B/zh active Active
- 2016-04-29 AU AU2016256573A patent/AU2016256573B2/en not_active Ceased
- 2016-04-29 MA MA41977A patent/MA41977B1/fr unknown
- 2016-04-29 TN TNP/2017/000428A patent/TN2017000428A1/en unknown
- 2016-04-29 HR HRP20191180TT patent/HRP20191180T1/hr unknown
- 2016-04-29 SG SG11201708822PA patent/SG11201708822PA/en unknown
- 2016-04-29 PL PL16720101T patent/PL3288944T3/pl unknown
- 2016-04-29 MY MYPI2017001597A patent/MY182382A/en unknown
- 2016-04-29 EA EA201792157A patent/EA031946B1/ru not_active IP Right Cessation
- 2016-04-29 CA CA2983563A patent/CA2983563A1/en active Pending
- 2016-04-29 HK HK18111408.3A patent/HK1252098B/en unknown
- 2016-04-29 MX MX2017013785A patent/MX375737B/es active IP Right Grant
- 2016-04-29 PT PT16720101T patent/PT3288944T/pt unknown
- 2016-04-29 HU HUE16720101 patent/HUE044244T2/hu unknown
- 2016-04-29 LT LTEP16720101.1T patent/LT3288944T/lt unknown
- 2016-04-29 GE GEAP201614615A patent/GEP20207058B/en unknown
- 2016-04-29 ES ES16720101T patent/ES2735422T3/es active Active
- 2016-04-29 BR BR112017023182-4A patent/BR112017023182B1/pt not_active IP Right Cessation
- 2016-04-29 WO PCT/EP2016/059583 patent/WO2016174188A1/en not_active Ceased
- 2016-04-29 UA UAA201710625A patent/UA123050C2/uk unknown
- 2016-04-29 JP JP2017556677A patent/JP6663930B2/ja active Active
- 2016-04-29 US US15/142,116 patent/US20160318939A1/en not_active Abandoned
- 2016-04-29 DK DK16720101.1T patent/DK3288944T3/da active
- 2016-04-29 SI SI201630319T patent/SI3288944T1/sl unknown
- 2016-04-29 ME MEP-2019-186A patent/ME03414B/me unknown
-
2017
- 2017-06-06 US US15/615,380 patent/US10011606B2/en active Active
- 2017-10-10 ZA ZA2017/06847A patent/ZA201706847B/en unknown
- 2017-10-12 CO CONC2017/0010399A patent/CO2017010399A2/es unknown
- 2017-10-24 GT GT201700223A patent/GT201700223A/es unknown
- 2017-10-26 CL CL2017002719A patent/CL2017002719A1/es unknown
- 2017-10-27 EC ECIEPI201772228A patent/ECSP17072228A/es unknown
- 2017-10-29 IL IL255316A patent/IL255316B/en unknown
- 2017-10-30 DO DO2017000254A patent/DOP2017000254A/es unknown
- 2017-10-30 PH PH12017501990A patent/PH12017501990B1/en unknown
-
2018
- 2018-06-07 US US16/002,116 patent/US10858362B2/en active Active
-
2019
- 2019-07-15 CY CY20191100751T patent/CY1121806T1/el unknown
-
2020
- 2020-10-26 US US17/079,951 patent/US11472810B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191180T1 (hr) | Imidazopirazinoni kao inhibitori pde1 | |
| JP2018514552A5 (OSRAM) | ||
| HRP20201326T1 (hr) | Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja | |
| RU2019108717A (ru) | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов | |
| HRP20201331T1 (hr) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-oni i 1,5-dihidro-4h-pirazolo[3,4-c]pirimidin-4-oni kao inhibitori pde1 | |
| JP6510068B2 (ja) | 新規なビフェニル化合物又はその塩 | |
| RU2016137169A (ru) | Гетероциклические соединения, способ их получения и их применение | |
| JP2019535664A5 (OSRAM) | ||
| RU2017111888A (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
| RU2015100213A (ru) | Замещенные соединения пиридин азолопиримидин-5-(6н)-она | |
| WO2025049746A1 (en) | Compositions comprising werner syndrome helicase inhibitors and methods of using the same | |
| HRP20200556T1 (hr) | Novi (hetero) aril-supstituirani-piperidinil derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| AU2018381004A1 (en) | Heterocyclic compounds as PRMT5 inhibitors | |
| ME02601B (me) | Novi derivati indolizina, postupak njihove pripreme i farmaceutski preparati koji ih sadrže za liječenje karcinoma | |
| JP2015526395A5 (OSRAM) | ||
| JP2013515729A5 (OSRAM) | ||
| MX2012004289A (es) | Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina. | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| TW202438496A (zh) | 噁二唑暫時受體電位通道抑制劑 | |
| JP2019504901A5 (OSRAM) | ||
| KR20200009068A (ko) | 신규 비페닐 화합물 또는 그의 염 | |
| RU2010128543A (ru) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов | |
| WO2016032921A1 (en) | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| JP2023549055A (ja) | 複素環式スピロ化合物及びその使用方法 | |
| PE20120900A1 (es) | Compuestos heterociclicos de fenoximetilo |